Modern Sun Worshippers
People travel for a lot of reasons. Some tourists go to see battlefields or religious shrines 1. Others are looking for culture, or simply want to have their pictures taken 2 in front of famous places. But most European tourists are looking for a sunny beach to lie on 3.
Northern Europeans are willing to pay a lot of money and put up with a lot of inconveniences for the sun because they have so little of it 4. Residents of cities like London,Copenhagen, andAmsterdamspend a lot of their winter in the dark because the days are so short, and much of the rest of the year in the rain 5. This is the reason theMediterranean 6 has always attracted them. Every summer, more than 25 million people travel to Mediterranean resorts 7 and beaches for their vacation. They all come for the same reason: sun!
The huge crowds mean lots of money for the economies of Mediterranean countries.Italy"s 30,000 hotels are booked solid 8 every summer. And 13 million people camp out on French beaches, parks, and roadsides.Spain"s long sandy coastline attracts more people than anywhere else. 37 million tourists visit yearly, or one tourist for every person living inSpain 9.
But there are signs that the area is getting more tourism than it can handle. TheMediterraneanis already one of the most polluted seas on earth. And with increased tourism ,it"s getting worse. The French can"t figure out 10 what to do with all the garbage left by campers around St. Tropez. And in many places, swimming is dangerous because of pollution.
None of this, however, is spoiling 11 anyone"s fun. TheMediterraneangets more popular every year with tourists. Obviously, they don"t go there for clean water and solitude 12. They tolerate traffic jams 13 and seem to like crowded beaches. They don"t even mind the pollution. No matter how dirty the water is, the coastline still looks beautiful. And as long as 14 the sun shines, it"s still better thanin the cold rain inBerlin,London, orOslo.
词汇:
battlefield / "bætlfi:ld/n.战场,疆场
inconvenience /inkən"vi:njəns/n.带来麻烦的事情,不便
resident /"rezidənt/n.居住者,居民
Copenhagen /,kəupən"heigən/n.哥本哈根(丹麦首都)
Amsterdam /,æmstə"dæm/n.阿姆斯特丹(荷兰首都)
vacation /və"keiʃən/n.假期,休假
coastline /"kəustlain/n.海岸线
tourism / "tuərizm/n.旅游,观光
pollute /pə"lu:t/vt.弄脏,污染
garbage /"ga:bidʒ/n.废物,垃圾
camper /"kæmpə/n.宿营者
Berlin /bə:"lin/n.柏林(德国首都)
Oslo /"ɔzləu/n.奥斯陆(挪威首都)
economy /i"kɔnəmi/n.经济状况,经济;节省,节约
注释:
1.religious shrine:zōng jiāo 圣殿
2.have their pictures taken:请别人为他们照相
3.But most European tourists are looking for a sunny beach to lie on.但大多数欧洲游客愿意寻找阳光充足的海滩晒日光浴。注意look for和fmd的区别。look for是“找”的过程,常解释为“寻找”,find是“找”的结果,所以常解释为“找到”。不妨体会一下它们的差别:I"ve been looking for my lost watch and haven"t found it yet.
4.Northern Europeans are willing to pay a lot of money and put up with a lot of inconveniences for the sun because they have so little of it.北欧人心甘情愿花大笔金钱,容忍诸多不便去获得阳光,因为阳光对他们来说太难得了。
5.Residents of cities like London, Copenhagen, and Amsterdam spend a lot of their winter in the dark because the days are so short, and much of the rest of the year in the rain.由于白天很短,像伦敦、哥本哈根和阿姆斯特丹的居民在冬季的大部分时间里,都是在昏暗中度过的,而其余的季节又都是阴雨连绵。这句点出了北欧阴冷潮湿,日短夜长的气候特征,也就解释了欧洲游客执著追求温暖明媚阳光的原因。
6.the Mediterranean:地中海地区
7.resorts:指常去的地方,胜地
8.be booked solid:全部客满
9.37 million tourists visit yearly ,or one tourist for every person living in Spain.每年有3 700多万游客,换句话说,旅游者与西班牙居民人数相当,即为1:1。
10.figure out:此处指“想出”,它还有“算出;明白;断定”等意。
11.spoil:原意为“损坏;宠坏”,此处指“破坏兴致”。
12.solitude:意为“独居,独处”,文中指清静自在。
13.traffic jams:交通堵塞
14.as long as:意为“只要;在……情况下”,引导条件状语从句。又如:I"m happy as long as you are happy.
The latter half of the last sentence in paragraph 3, i. e.,"or one tourist for every person living in Spain" means________.
A:all the 37 million people living in Spainare tourists B:every year almost as many tourists visit Spainas there are people living in that country C:every person living in Spainhas to take care of a tourist D:every Spanish is visited by a tourist every year
Animal studies are under way, human trial protocols are taking shape and drug makers are on alert. All the international health community needs now is a human vaccine for the bird flu pandemic sweeping a cluster of Asian countries.
The race for a vaccine began after the first human case emerged in Hong Kong in 1997. Backed by the World Health Organization (WHO), three research teams in the US and UK are trying to create a seed virus for a new vaccine. Their task is formidable, but researchers remain optimistic." There are obstacles, but most of the obstacles have been treated sensibly," says Richard Webby, a virologist at St. Jude Children’s Research Hospital in Memphis, Tennessee.
The biggest challenge is likely to be the rapidly mutating virus. Candidate vaccines produced last year against the H5N1 virus are ineffective against this year’s strain. Scientists will have to constantly monitor the changes and try to tailor the vaccine as the virus mutates. They can’t wait to see which one comes next.
The urgency stems from fears that I-ISN1 will combine with a human flu virus, creating a pathogen(病原体) that could be transmitted from person to person. But if people have no immunity to the virus, the strain may not mutate as rapidly in people as it does in birds.
To quickly generate the vaccine, researchers are using reverse genetics, which allows them to skip the long process of searching through reassorted viruses for the correct genetic combination. Instead, scientists clone sequences for hemagglutinin(红血球凝聚素) and neuraminidase(神经氨酸苷酶), the two key proteins in the virus. The sequences are then combined with human influenza genes to create a customized reference strain.
Because products developed with reverse genetics have never been tested in humans, the candidate vaccines will first have to clear regulatory review. In anticipation, the US Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) are both preparing pandemic response plans. The EMEA has produced a fist-track licensing program, an industry task force and detailed guidance for potential applicants.
In Europe, a reassortant influenza virus -- but not the inactivated vaccine -- produced by reverse genetics would be considered a genetically modified organism, and manufacturers would need approval from their national or local safety authorities. The WHO has prepared a preliminary biosafety risk assessment of pilot-lot vaccine, which could help speed up the review.
A preliminary version of their protocol calls for several hundred subjects, beginning with a group of young adults and gradually expanding to include those most susceptible to the flu -- children and the elderly." If we had product," says Lambert," it would probably be a couple of months at the earliest before we have early data in healthy adults./
Which of the following can be inferred from the passage
A:there is already a case in which the virus is transmitted from person to person. B:american scientists take the pandemic more seriously than European ones. C:the effect of candidate vaccines can last more than one year. D:the manufacture of the vaccine must be authorized by safety authorities.
Text 2
Animal studies are under way, human
trial protocols are taking shape and drug makers are on alert. All the
international health community needs now is a human vaccine for the bird flu
pandemic sweeping a cluster of Asian countries. The race for a vaccine began after the first human case emerged in Hong Kong in 1997. Backed by the World Health Organization (WHO), three research teams in the US and UK are trying to create a seed virus for a new vaccine. Their task is formidable, but researchers remain optimistic." There are obstacles, but most of the obstacles have been treated sensibly," says Richard Webby, a virologist at St. Jude Children’s Research Hospital in Memphis, Tennessee. The biggest challenge is likely to be the rapidly mutating virus. Candidate vaccines produced last year against the H5N1 virus are ineffective against this year’s strain. Scientists will have to constantly monitor the changes and try to tailor the vaccine as the virus mutates. They can’t wait to see which one comes next. The urgency stems from fears that I-ISN1 will combine with a human flu virus, creating a pathogen(病原体) that could be transmitted from person to person. But if people have no immunity to the virus, the strain may not mutate as rapidly in people as it does in birds. To quickly generate the vaccine, researchers are using reverse genetics, which allows them to skip the long process of searching through reassorted viruses for the correct genetic combination. Instead, scientists clone sequences for hemagglutinin(红血球凝聚素) and neuraminidase(神经氨酸苷酶), the two key proteins in the virus. The sequences are then combined with human influenza genes to create a customized reference strain. Because products developed with reverse genetics have never been tested in humans, the candidate vaccines will first have to clear regulatory review. In anticipation, the US Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) are both preparing pandemic response plans. The EMEA has produced a fist-track licensing program, an industry task force and detailed guidance for potential applicants. In Europe, a reassortant influenza virus -- but not the inactivated vaccine -- produced by reverse genetics would be considered a genetically modified organism, and manufacturers would need approval from their national or local safety authorities. The WHO has prepared a preliminary biosafety risk assessment of pilot-lot vaccine, which could help speed up the review. A preliminary version of their protocol calls for several hundred subjects, beginning with a group of young adults and gradually expanding to include those most susceptible to the flu -- children and the elderly." If we had product," says Lambert," it would probably be a couple of months at the earliest before we have early data in healthy adults." |
A:there is already a case in which the virus is transmitted from person to person. B:american scientists take the pandemic more seriously than European ones. C:the effect of candidate vaccines can last more than one year. D:the manufacture of the vaccine must be authorized by safety authorities.
The last paragraph shows that _______.
A:Turner's interest is presently centered on chain restaurants B:Turner is such a changeable person on business matters C:Turner will never give up his independent film company D:Turner is a businessman full of imagination
Animal studies are under way, human trial protocols are taking shape and drug makers are on alert. All the international health community needs now is a human vaccine for the bird flu pandemic sweeping a cluster of Asian countries.
The race for a vaccine began after the first human case emerged in Hong Kong in 1997. Backed by the World Health Organization (WHO), three research teams in the US and UK are trying to create a seed virus for a new vaccine. Their task is formidable, but researchers remain optimistic." There are obstacles, but most of the obstacles have been treated sensibly," says Richard Webby, a virologist at St. Jude Children’s Research Hospital in Memphis, Tennessee.
The biggest challenge is likely to be the rapidly mutating virus. Candidate vaccines produced last year against the H5N1 virus are ineffective against this year’s strain. Scientists will have to constantly monitor the changes and try to tailor the vaccine as the virus mutates. They can’t wait to see which one comes next.
The urgency stems from fears that I-ISN1 will combine with a human flu virus, creating a pathogen(病原体) that could be transmitted from person to person. But if people have no immunity to the virus, the strain may not mutate as rapidly in people as it does in birds.
To quickly generate the vaccine, researchers are using reverse genetics, which allows them to skip the long process of searching through reassorted viruses for the correct genetic combination. Instead, scientists clone sequences for hemagglutinin(红血球凝聚素) and neuraminidase(神经氨酸苷酶), the two key proteins in the virus. The sequences are then combined with human influenza genes to create a customized reference strain.
Because products developed with reverse genetics have never been tested in humans, the candidate vaccines will first have to clear regulatory review. In anticipation, the US Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) are both preparing pandemic response plans. The EMEA has produced a fist-track licensing program, an industry task force and detailed guidance for potential applicants.
In Europe, a reassortant influenza virus -- but not the inactivated vaccine -- produced by reverse genetics would be considered a genetically modified organism, and manufacturers would need approval from their national or local safety authorities. The WHO has prepared a preliminary biosafety risk assessment of pilot-lot vaccine, which could help speed up the review.
A preliminary version of their protocol calls for several hundred subjects, beginning with a group of young adults and gradually expanding to include those most susceptible to the flu -- children and the elderly." If we had product," says Lambert," it would probably be a couple of months at the earliest before we have early data in healthy adults.
A:there is already a case in which the virus is transmitted from person to person B:american scientists take the pandemic more seriously than European ones C:the effect of candidate vaccines can last more than one year D:the manufacture of the vaccine must be authorized by safety authorities
________ leaves the room last ought to turn off the lights.
A:Anyone B:The person C:Whoever D:Who
给出下列的不完整的类代码,则下列的哪个语句可以加到横线处 class Person { String name,department; int age; public Person( String n ){ name = n;} public Person( String n,int a ) { name = n;age = a;} public Person( String n,String d,int a ) { _____________ department = d; } }
A:Person(n,; B:this(Person(n, ); C:this(n,; D:this(name,ag;
( )Finish cating lunch last ought to wash the dishes.
A:The person B:Whoever C:Anyone D:Who